FDA Approves IBRANCE (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
Pfizer announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for IBRANCE (palbociclib) in combination…
Read More...
Read More...
